Impact of Benzodiazepines and Illness Duration on Obsessive–Compulsive Disorder during COVID-19 in Italy: Exploring Symptoms’ Evolutionary Benefits
Abstract
Share and Cite
D’Urso, G.; Magliacano, A.; Manzo, M.; Pomes, M.V.; Iuliano, C.; Iasevoli, F.; Dell’Osso, B.; de Bartolomeis, A. Impact of Benzodiazepines and Illness Duration on Obsessive–Compulsive Disorder during COVID-19 in Italy: Exploring Symptoms’ Evolutionary Benefits. Brain Sci. 2024, 14, 338. https://doi.org/10.3390/brainsci14040338
D’Urso G, Magliacano A, Manzo M, Pomes MV, Iuliano C, Iasevoli F, Dell’Osso B, de Bartolomeis A. Impact of Benzodiazepines and Illness Duration on Obsessive–Compulsive Disorder during COVID-19 in Italy: Exploring Symptoms’ Evolutionary Benefits. Brain Sciences. 2024; 14(4):338. https://doi.org/10.3390/brainsci14040338
Chicago/Turabian StyleD’Urso, Giordano, Alfonso Magliacano, Marco Manzo, Mattia Vittorio Pomes, Carla Iuliano, Felice Iasevoli, Bernardo Dell’Osso, and Andrea de Bartolomeis. 2024. "Impact of Benzodiazepines and Illness Duration on Obsessive–Compulsive Disorder during COVID-19 in Italy: Exploring Symptoms’ Evolutionary Benefits" Brain Sciences 14, no. 4: 338. https://doi.org/10.3390/brainsci14040338
APA StyleD’Urso, G., Magliacano, A., Manzo, M., Pomes, M. V., Iuliano, C., Iasevoli, F., Dell’Osso, B., & de Bartolomeis, A. (2024). Impact of Benzodiazepines and Illness Duration on Obsessive–Compulsive Disorder during COVID-19 in Italy: Exploring Symptoms’ Evolutionary Benefits. Brain Sciences, 14(4), 338. https://doi.org/10.3390/brainsci14040338